[SCHEDULE 13G/A] Tango Therapeutics, Inc. Amended Passive Investment Disclosure
Tango Therapeutics, Inc. amendment reports that TCG Crossover II entities and Chen Yu together beneficially hold 11,597,737 shares of Common Stock, representing 8.1% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tango Therapeutics, Inc. amendment reports that TCG Crossover II entities and Chen Yu together beneficially hold 11,597,737 shares of Common Stock, representing 8.1% of the class. The disclosure states this position includes 1,066,666 shares underlying pre-funded warrants exercisable within 60 days.
The filing cites a pool of 143,735,517 shares used for calculation, reflecting 142,668,851 shares outstanding as of February 26, 2026 plus the exercisable pre-funded warrants. It notes a Beneficial Ownership Limitation that caps exercises at 9.99%.
Insights
Large passive holding disclosed; voting and disposition powers are shared through fund structures.
The filing documents 11,597,737 shares held with shared voting and dispositive power by TCG Crossover GP II and related entities. The position is quantified against a 143,735,517-share denominator that includes exercisable pre-funded warrants as of February 26, 2026.
Key dependencies include the Beneficial Ownership Limitation (9.99%) on pre-funded warrant exercises and the fund governance that attributes shared power. Subsequent filings would show any exercises or transfers affecting this percentage.
Disclosure clarifies control attribution via GP and managing member relationships.
The statement explains that TCG Crossover GP II is general partner of TCG Crossover II and that Chen Yu, as sole managing member, may be deemed to share voting, investment and dispositive power over the reported 11,597,737 shares. The comment ties holdings to record ownership by TCG Crossover II.
Investors should note the filing’s joint-filing agreement and the explicit disclaimer of group status. Any change in fund composition, warrant exercises, or governance arrangements would alter reported power; timing of such events is not stated here.
Key Figures
Key Terms
Pre-Funded Warrants financial
Beneficial Ownership Limitation regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake do TCG Crossover entities hold in Tango Therapeutics (TNGX)?
How was the percent ownership calculated in the Schedule 13G/A?
Does the filing limit warrant exercises for the reporting persons?
AI-generated analysis. How Rhea-AI works. Not financial advice.